HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Jean-Louis Chiasson Selected Research

Acarbose

11/2017Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial.
7/2014Rationale for and design of the Acarbose Cardiovascular Evaluation (ACE) trial.
2/2010Development and validation of a risk-score model for subjects with impaired glucose tolerance for the assessment of the risk of type 2 diabetes mellitus-The STOP-NIDDM risk-score.
12/2007Prevention of Type 2 diabetes: fact or fiction?
10/2007Who should benefit from the use of alpha-glucosidase inhibitors?
4/2007Single nucleotide polymorphisms of the peroxisome proliferator-activated receptor-alpha gene (PPARA) influence the conversion from impaired glucose tolerance to type 2 diabetes: the STOP-NIDDM trial.
8/2006Single nucleotide polymorphisms of the HNF4alpha gene are associated with the conversion to type 2 diabetes mellitus: the STOP-NIDDM trial.
1/2006Pharmacological and surgical intervention for the prevention of diabetes.
1/2006Acarbose for the prevention of diabetes, hypertension, and cardiovascular disease in subjects with impaired glucose tolerance: the Study to Prevent Non-Insulin-Dependent Diabetes Mellitus (STOP-NIDDM) Trial.
4/2005Acarbose in the prevention of cardiovascular disease in subjects with impaired glucose tolerance and type 2 diabetes mellitus.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Jean-Louis Chiasson Research Topics

Disease

28Type 2 Diabetes Mellitus (MODY)
12/2019 - 06/2002
14Glucose Intolerance
11/2017 - 06/2002
8Cardiovascular Diseases (Cardiovascular Disease)
07/2014 - 07/2003
6Insulin Resistance
04/2015 - 07/2006
5Hyperglycemia
01/2018 - 04/2003
3Fibrosis (Cirrhosis)
01/2018 - 10/2014
3Body Weight (Weight, Body)
04/2017 - 12/2012
3Type 1 Diabetes Mellitus (Autoimmune Diabetes)
12/2016 - 08/2008
3Hypertension (High Blood Pressure)
02/2010 - 07/2003
2Diabetic Nephropathies (Diabetic Nephropathy)
01/2020 - 01/2018
2Hypertrophy
01/2018 - 04/2015
2Coronary Disease (Coronary Heart Disease)
11/2017 - 01/2006
2Flatulence
04/2017 - 06/2002
2Myocardial Infarction
10/2014 - 10/2004
2Obesity
10/2014 - 03/2005
1Gastrointestinal Diseases (Functional Gastrointestinal Disorders)
11/2017
1Chronic Disease (Chronic Diseases)
01/2016
1Inflammation (Inflammations)
04/2015
1Cardiomyopathies (Cardiomyopathy)
04/2015
1Weight Loss (Weight Reduction)
12/2012
1Injection Site Reaction
12/2012
1Prediabetic State (Prediabetes)
12/2007
1Cystic Fibrosis (Mucoviscidosis)
11/2007
1Hyperlipidemias (Hyperlipidemia)
09/2007
1Hyperinsulinism (Hyperinsulinemia)
04/2007
1Gestational Diabetes (Gestational Diabetes Mellitus)
01/2006

Drug/Important Bio-Agent (IBA)

15Glucose (Dextrose)FDA LinkGeneric
12/2016 - 06/2002
14AcarboseFDA LinkGeneric
11/2017 - 06/2002
7Insulin (Novolin)FDA Link
07/2015 - 04/2003
3Proteins (Proteins, Gene)FDA Link
01/2020 - 10/2014
3Blood Glucose (Blood Sugar)IBA
11/2016 - 07/2014
3Metformin (Glucophage)FDA LinkGeneric
07/2015 - 01/2006
2Biomarkers (Surrogate Marker)IBA
10/2019 - 05/2007
2EnzymesIBA
01/2018 - 02/2007
2Streptozocin (Streptozotocin)FDA Link
01/2018 - 08/2008
2Pharmaceutical PreparationsIBA
01/2018 - 11/2017
2Reactive Oxygen Species (Oxygen Radicals)IBA
01/2018 - 04/2015
2GlucosidasesIBA
11/2017 - 07/2014
2Dietary Carbohydrates (Carbohydrate, Dietary)IBA
04/2017 - 01/2008
2CarbohydratesIBA
04/2017 - 01/2008
2Hormones (Hormone)IBA
12/2016 - 04/2003
2LiraglutideFDA Link
09/2015 - 07/2015
2Insulin Glargine (Lantus)FDA Link
09/2015 - 07/2015
2Oxytocin (Pitocin)FDA LinkGeneric
04/2015 - 10/2014
2Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
09/2007 - 05/2007
2KetonesIBA
02/2007 - 04/2003
2Glycoside Hydrolase InhibitorsIBA
07/2005 - 07/2003
1Cytochrome P-450 Enzyme System (Cytochrome P450)IBA
12/2019
1CholesterolIBA
10/2019
1Cytochrome P-450 CYP3AIBA
10/2019
1CytochromesIBA
01/2018
1NADPH Oxidase 4IBA
01/2018
1AlbuminsIBA
01/2018
1CreatinineIBA
01/2018
1PlatinumIBA
01/2016
1Hypoglycemic Agents (Hypoglycemics)IBA
07/2015
1Atrial Natriuretic Factor (ANF)IBA
04/2015
1Protein Kinases (Protein Kinase)IBA
04/2015
1Brain Natriuretic Peptide (Natrecor)FDA Link
04/2015
1Phosphotransferases (Kinase)IBA
04/2015
1ResistinIBA
04/2015
1Natriuretic PeptidesIBA
10/2014
1Nitric Oxide Synthase Type III (Endothelial Nitric Oxide Synthase)IBA
10/2014
1GATA4 Transcription FactorIBA
10/2014
1Tretinoin (Retinoic Acid)FDA LinkGeneric
10/2014
1Messenger RNA (mRNA)IBA
10/2014
1Corn Oil (Oil, Corn)IBA
10/2014
1CollagenIBA
10/2014
1Sitagliptin Phosphate (Januvia)FDA Link
12/2012
1taspoglutideIBA
12/2012
1Glucagon-Like Peptide 1 (GLP 1)IBA
12/2012
1Triglycerides (Triacylglycerol)IBA
02/2010
1C-Reactive ProteinIBA
01/2008
1Glycated Hemoglobin (Glycosylated Hemoglobin)IBA
01/2008
1Rosiglitazone (Avandia)FDA Link
12/2007
1Ramipril (Altace)FDA LinkGeneric
12/2007
1BiguanidesIBA
10/2007
1ThiazolidinedionesIBA
10/2007
1Hemoglobin AIBA
10/2007
1CytokinesIBA
09/2007
1LipidsIBA
05/2007
1Nonesterified Fatty Acids (NEFA)IBA
05/2007
1PPAR alphaIBA
04/2007
1Somatostatin (Somatotropin Release-Inhibiting Factor)IBA
04/2007
1MetallothioneinIBA
04/2007
1Biological ProductsIBA
04/2007
1Free RadicalsIBA
04/2007
1Mitogen-Activated Protein Kinase Kinases (MEKs)IBA
02/2007
1Ketone BodiesIBA
02/2007
12- (2- amino- 3- methoxyphenyl)- 4H- 1- benzopyran- 4- oneIBA
02/2007
1Vanadates (Orthovanadate)IBA
02/2007
1Peroxisome Proliferator-Activated Receptors (PPAR)IBA
07/2006
1Fatty Acids (Saturated Fatty Acids)IBA
07/2006
1PPAR deltaIBA
07/2006
1Troglitazone (Rezulin)FDA Link
01/2006

Therapy/Procedure

4Therapeutics
11/2017 - 10/2004
4Glycemic Control
04/2017 - 10/2004
1Secondary Prevention
11/2017
1Artificial Pancreas
12/2016
1Reducing Diet
12/2007